scholarly journals Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

Virology ◽  
2014 ◽  
Vol 454-455 ◽  
pp. 139-144 ◽  
Author(s):  
John T. Bates ◽  
Christopher J. Keefer ◽  
James C. Slaughter ◽  
Daniel W. Kulp ◽  
William R. Schief ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Neutralizing Monoclonal Antibody ◽  
Syncytial Virus

scholarly journals Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice

1998 ◽  
Vol 72 (1) ◽  
pp. 807-810 ◽  
Author(s):  
C. Bourgeois ◽  
J. B. Bour ◽  
L. S. Aho ◽  
P. Pothier
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Respiratory Syncytial Virus ◽  
Lung Infection ◽  
Neutralizing Monoclonal Antibody ◽  
Rsv Infection ◽  
Syncytial Virus ◽  
Complementarity Determining Region ◽  
Single Peptide

ABSTRACT Immunotherapy with antibodies against respiratory syncytial virus (RSV) is a treatment option given the absence of any vaccine or other available satisfactory treatment. We selected one of our monoclonal antibodies, RS-348, that is highly neutralizing. We showed that a single peptide (PEP3H) derived from complementarity-determining region 3 (CDR3) of its heavy chain was capable of neutralizing the virusin vitro. When intranasally administered 24 h before challenge, this peptide protected BALB/c mice against RSV lung infection. These results indicate that a single CDR can be effective against RSV infection.

scholarly journals Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice

2009 ◽  
Vol 90 (5) ◽  
pp. 1119-1123 ◽  
Author(s):  
Congrong Miao ◽  
Gertrud U. Radu ◽  
Hayat Caidi ◽  
Ralph A. Tripp ◽  
Larry J. Anderson ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Respiratory Syncytial Virus ◽  
Interferon Gamma ◽  
Virus Replication ◽  
Pulmonary Inflammation ◽  
Leukocyte Trafficking ◽  
Virus Clearance ◽  
Neutralizing Monoclonal Antibody ◽  
Rsv Infection ◽  
Syncytial Virus

Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-γ) production in the lungs of RSV-infected mice. Its F(ab′)2 component only mediates decreased leukocyte trafficking and IFN-γ production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Immunity ◽  
2021 ◽  
Author(s):  
Maryam Mukhamedova ◽  
Daniel Wrapp ◽  
Chen-Hsiang Shen ◽  
Morgan S.A. Gilman ◽  
Tracy J. Ruckwardt ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Antibody Responses ◽  
Virus Fusion ◽  
Syncytial Virus
Sign in / Sign up

Export Citation Format

Share Document